-
1
-
-
0034651022
-
Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules
-
Barrow, R.T., Healey, J.F., Gailani, D., Scandella, D. & Lollar, P. (2000) Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood, 95, 564-568.
-
(2000)
Blood
, vol.95
, pp. 564-568
-
-
Barrow, R.T.1
Healey, J.F.2
Gailani, D.3
Scandella, D.4
Lollar, P.5
-
2
-
-
77953158260
-
Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice
-
Bolliger, D., Szlam, F., Suzuki, N., Matsushita, T. & Tanaka, K.A. (2010) Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. Thrombosis & Haemostasis, 103, 1233-1238.
-
(2010)
Thrombosis & Haemostasis
, vol.103
, pp. 1233-1238
-
-
Bolliger, D.1
Szlam, F.2
Suzuki, N.3
Matsushita, T.4
Tanaka, K.A.5
-
3
-
-
84883764333
-
Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy
-
Brooks, A.R., Sim, D., Gritzan, U., Patel, C., Blasko, E., Feldman, R.I., Tang, L., Ho, E., Zhao, X.Y., Apeler, H. & Murphy, J.E. (2013) Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy. Journal of Thrombosis & Haemostasis, 11, 1699-1706.
-
(2013)
Journal of Thrombosis & Haemostasis
, vol.11
, pp. 1699-1706
-
-
Brooks, A.R.1
Sim, D.2
Gritzan, U.3
Patel, C.4
Blasko, E.5
Feldman, R.I.6
Tang, L.7
Ho, E.8
Zhao, X.Y.9
Apeler, H.10
Murphy, J.E.11
-
4
-
-
84920984860
-
Factor XI antisense oligonucleotide for prevention of venous thrombosis
-
Büller, H.R., Bethune, C., Bhanot, S., Gailani, D., Monia, B.P., Raskob, G.E., Segers, A., Verhamme, P. & Weitz, J.I. (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. New England Journal of Medicine, 372, 232-240.
-
(2015)
New England Journal of Medicine
, vol.372
, pp. 232-240
-
-
Büller, H.R.1
Bethune, C.2
Bhanot, S.3
Gailani, D.4
Monia, B.P.5
Raskob, G.E.6
Segers, A.7
Verhamme, P.8
Weitz, J.I.9
-
5
-
-
78650988916
-
Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
-
Bunce, M.W., Toso, R. & Camire, R.M. (2011) Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood, 117, 290-298.
-
(2011)
Blood
, vol.117
, pp. 290-298
-
-
Bunce, M.W.1
Toso, R.2
Camire, R.M.3
-
6
-
-
0033214353
-
"Normal" thrombin generation
-
Butenas, S., van't Veer, C. & Mann, K.G. (1999) "Normal" thrombin generation. Blood, 94, 2169-2178.
-
(1999)
Blood
, vol.94
, pp. 2169-2178
-
-
Butenas, S.1
van't Veer, C.2
Mann, K.G.3
-
7
-
-
0344420226
-
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
-
Caliceti, P. & Veronese, F.M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Advanced Drug Delivery Reviews, 55, 1261-1277.
-
(2003)
Advanced Drug Delivery Reviews
, vol.55
, pp. 1261-1277
-
-
Caliceti, P.1
Veronese, F.M.2
-
8
-
-
84928764693
-
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
-
Chowdary, P., Lethagen, S., Friedrich, U., Brand, B., Hay, C., Abdul Karim, F., Klamroth, R., Knoebl, P., Laffan, M., Mahlangu, J., Miesbach, W., Dalsgaard Nielsen, J., Martin-Salces, M. & Angchaisuksiri, P. (2015) Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. Journal of Thrombosis & Haemostasis, 13, 743-754.
-
(2015)
Journal of Thrombosis & Haemostasis
, vol.13
, pp. 743-754
-
-
Chowdary, P.1
Lethagen, S.2
Friedrich, U.3
Brand, B.4
Hay, C.5
Abdul Karim, F.6
Klamroth, R.7
Knoebl, P.8
Laffan, M.9
Mahlangu, J.10
Miesbach, W.11
Dalsgaard Nielsen, J.12
Martin-Salces, M.13
Angchaisuksiri, P.14
-
9
-
-
84880586354
-
Gene therapy for hemophilia
-
Chuah, M.K., Evens, H. & VandenDriessche, T. (2013) Gene therapy for hemophilia. Journal of Thrombosis & Haemostasis, 11, 99-110.
-
(2013)
Journal of Thrombosis & Haemostasis
, vol.11
, pp. 99-110
-
-
Chuah, M.K.1
Evens, H.2
VandenDriessche, T.3
-
10
-
-
84919491430
-
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
-
Collins, P.W., Young, G., Knobe, K., Karim, F.A., Angchaisuksiri, P., Banner, C., Gursel, T., Mahlangu, J., Matsushita, T., Mauser-Bunschoten, E.P., Oldenburg, J., Walsh, C.E., Negrier, C. & Paradigm, I. (2014) Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood, 124, 3880-3886.
-
(2014)
Blood
, vol.124
, pp. 3880-3886
-
-
Collins, P.W.1
Young, G.2
Knobe, K.3
Karim, F.A.4
Angchaisuksiri, P.5
Banner, C.6
Gursel, T.7
Mahlangu, J.8
Matsushita, T.9
Mauser-Bunschoten, E.P.10
Oldenburg, J.11
Walsh, C.E.12
Negrier, C.13
Paradigm, I.14
-
11
-
-
84898028710
-
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
-
Coyle, T.E., Reding, M.T., Lin, J.C., Michaels, L.A., Shah, A. & Powell, J. (2014) Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. Journal of Thrombosis and Haemostasis, 12, 488-496.
-
(2014)
Journal of Thrombosis and Haemostasis
, vol.12
, pp. 488-496
-
-
Coyle, T.E.1
Reding, M.T.2
Lin, J.C.3
Michaels, L.A.4
Shah, A.5
Powell, J.6
-
12
-
-
84894407141
-
Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499
-
Dockal, M., Pachlinger, R., Hartmann, R., Knappe, S., Sorensen, B., Yen Wong, W., Conlan, M., Cecerle, M., Ewenstein, B., Ehrlich, H. & Scheiflinger, F. (2012) Biological explanation of clinically observed elevation of TFPI plasma levels after treatment with TFPI-antagonistic aptamer BAX 499. Blood, 120, Abstract 1104.
-
(2012)
Blood
, vol.120
-
-
Dockal, M.1
Pachlinger, R.2
Hartmann, R.3
Knappe, S.4
Sorensen, B.5
Yen Wong, W.6
Conlan, M.7
Cecerle, M.8
Ewenstein, B.9
Ehrlich, H.10
Scheiflinger, F.11
-
13
-
-
84931956043
-
Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators
-
Dodt, J., Hubbard, A.R., Wicks, S.J., Gray, E., Neugebauer, B., Charton, E. & Silvester, G. (2015) Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia, 21, 543-549.
-
(2015)
Haemophilia
, vol.21
, pp. 543-549
-
-
Dodt, J.1
Hubbard, A.R.2
Wicks, S.J.3
Gray, E.4
Neugebauer, B.5
Charton, E.6
Silvester, G.7
-
14
-
-
84859192874
-
Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs
-
Dumont, J.A., Liu, T., Low, S.C., Zhang, X., Kamphaus, G., Sakorafas, P., Fraley, C., Drager, D., Reidy, T., McCue, J., Franck, H.W.G., Merricks, E.P., Nichols, T.C., Bitonti, A.J., Pierce, G.F. & Jiang, H. (2012) Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 119, 3024-3030.
-
(2012)
Blood
, vol.119
, pp. 3024-3030
-
-
Dumont, J.A.1
Liu, T.2
Low, S.C.3
Zhang, X.4
Kamphaus, G.5
Sakorafas, P.6
Fraley, C.7
Drager, D.8
Reidy, T.9
McCue, J.10
Franck, H.W.G.11
Merricks, E.P.12
Nichols, T.C.13
Bitonti, A.J.14
Pierce, G.F.15
Jiang, H.16
-
15
-
-
84870496347
-
The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy
-
Finn, J.D., Nichols, T.C., Svoronos, N., Merricks, E.P., Bellenger, D.A., Zhou, S., Simioni, P., High, K.A. & Arruda, V.R. (2012) The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood, 120, 4521-4523.
-
(2012)
Blood
, vol.120
, pp. 4521-4523
-
-
Finn, J.D.1
Nichols, T.C.2
Svoronos, N.3
Merricks, E.P.4
Bellenger, D.A.5
Zhou, S.6
Simioni, P.7
High, K.A.8
Arruda, V.R.9
-
16
-
-
33646765242
-
Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants
-
Gale, A.J., Radtke, K.P., Cunningham, M.A., Chamberlain, D., Pellequer, J.L. & Griffin, J.H. (2006) Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. Journal of Thrombosis and Haemostasis, 4, 1315-1322.
-
(2006)
Journal of Thrombosis and Haemostasis
, vol.4
, pp. 1315-1322
-
-
Gale, A.J.1
Radtke, K.P.2
Cunningham, M.A.3
Chamberlain, D.4
Pellequer, J.L.5
Griffin, J.H.6
-
17
-
-
84860317799
-
Porcine factor VIII
-
Giangrande, P.L. (2012) Porcine factor VIII. Haemophilia, 18, 305-309.
-
(2012)
Haemophilia
, vol.18
, pp. 305-309
-
-
Giangrande, P.L.1
-
18
-
-
0036845615
-
Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy
-
Hakeos, W.H., Miao, H., Sirachainan, N., Kemball-Cook, G., Saenko, E.L., Kaufman, R.J. & Pipe, S.W. (2002) Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy. Thrombosis & Haemostasis, 88, 781-787.
-
(2002)
Thrombosis & Haemostasis
, vol.88
, pp. 781-787
-
-
Hakeos, W.H.1
Miao, H.2
Sirachainan, N.3
Kemball-Cook, G.4
Saenko, E.L.5
Kaufman, R.J.6
Pipe, S.W.7
-
19
-
-
84922385618
-
FVIIa-CTP and FIX-CTP are novel long-acting coagulation factors with prolonged hemopstatic activity in haemophilic animal models
-
PO-TU-025
-
Hart, G., Monahan, P., Seligsohn, U., Zakar, M., Hershkovitz, O., Bar-Ilan, A. & Fima, E. (2012) FVIIa-CTP and FIX-CTP are novel long-acting coagulation factors with prolonged hemopstatic activity in haemophilic animal models. Haemophilia, 18(S3), 32. PO-TU-025.
-
(2012)
Haemophilia
, vol.18
, pp. 32
-
-
Hart, G.1
Monahan, P.2
Seligsohn, U.3
Zakar, M.4
Hershkovitz, O.5
Bar-Ilan, A.6
Fima, E.7
-
20
-
-
0029909770
-
The cDNA and derived amino acid sequence of porcine factor VIII
-
Healey, J.F., Lubin, I.M. & Lollar, P. (1996) The cDNA and derived amino acid sequence of porcine factor VIII. Blood, 88, 4209-4214.
-
(1996)
Blood
, vol.88
, pp. 4209-4214
-
-
Healey, J.F.1
Lubin, I.M.2
Lollar, P.3
-
21
-
-
80053366223
-
Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model
-
van Held en, P.M., Unterthurner, S., Hermann, C., Schuster, M., Ahmad, R.U., Schiviz, A.N., Weiller, M., Antoine, G., Turecek, P.L., Muchitsch, E.M., Schwarz, H.P. & Reipert, B.M. (2011) Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood, 118, 3698-3707.
-
(2011)
Blood
, vol.118
, pp. 3698-3707
-
-
van Held en, P.M.1
Unterthurner, S.2
Hermann, C.3
Schuster, M.4
Ahmad, R.U.5
Schiviz, A.N.6
Weiller, M.7
Antoine, G.8
Turecek, P.L.9
Muchitsch, E.M.10
Schwarz, H.P.11
Reipert, B.M.12
-
22
-
-
84899533543
-
Current status of haemophilia gene therapy
-
High, K.H., Nathwani, A., Spencer, T. & Lillicrap, D. (2014) Current status of haemophilia gene therapy. Haemophilia, 20, 43-49.
-
(2014)
Haemophilia
, vol.20
, pp. 43-49
-
-
High, K.H.1
Nathwani, A.2
Spencer, T.3
Lillicrap, D.4
-
23
-
-
77954506432
-
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
-
Iorio, A., Halimeh, S., Holzhauer, S., Goldenberg, N., Marchesini, E., Marcucci, M., Young, G., Bidlingmaier, C., Brandao, L.R., Ettingshausen, C.E., Gringeri, A., Kenet, G., Knofler, R., Kreuz, W., Kurnik, K., Manner, D., Santagostino, E., Mannucci, P.M. & Nowak-Gottl, U. (2010) Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis & Haemostasis, 8, 1256-1265.
-
(2010)
Journal of Thrombosis & Haemostasis
, vol.8
, pp. 1256-1265
-
-
Iorio, A.1
Halimeh, S.2
Holzhauer, S.3
Goldenberg, N.4
Marchesini, E.5
Marcucci, M.6
Young, G.7
Bidlingmaier, C.8
Brandao, L.R.9
Ettingshausen, C.E.10
Gringeri, A.11
Kenet, G.12
Knofler, R.13
Kreuz, W.14
Kurnik, K.15
Manner, D.16
Santagostino, E.17
Mannucci, P.M.18
Nowak-Gottl, U.19
-
24
-
-
84871015919
-
PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers
-
Ivens, I.A., Baumann, A., McDonald, T.A., Humphries, T.J., Michaels, L.A. & Mathew, P. (2013) PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia, 19, 11-20.
-
(2013)
Haemophilia
, vol.19
, pp. 11-20
-
-
Ivens, I.A.1
Baumann, A.2
McDonald, T.A.3
Humphries, T.J.4
Michaels, L.A.5
Mathew, P.6
-
25
-
-
84871660904
-
Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII
-
Kannicht, C., Ramstrom, M., Kohla, G., Tiemeyer, M., Casademunt, E., Walter, O. & Sandberg, H. (2013) Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thrombosis Research, 131, 78-88.
-
(2013)
Thrombosis Research
, vol.131
, pp. 78-88
-
-
Kannicht, C.1
Ramstrom, M.2
Kohla, G.3
Tiemeyer, M.4
Casademunt, E.5
Walter, O.6
Sandberg, H.7
-
26
-
-
84865571944
-
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A
-
Kempton, C.L., Abshire, T.C., Deveras, R.A., Hoots, W.K., Gill, J.C., Kessler, C.M., Key, N.S., Konkle, B.A., Kuriakose, P., Macfarlane, D.E. & Bergman, G. (2012) Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia, 18, 798-804.
-
(2012)
Haemophilia
, vol.18
, pp. 798-804
-
-
Kempton, C.L.1
Abshire, T.C.2
Deveras, R.A.3
Hoots, W.K.4
Gill, J.C.5
Kessler, C.M.6
Key, N.S.7
Konkle, B.A.8
Kuriakose, P.9
Macfarlane, D.E.10
Bergman, G.11
-
27
-
-
84870302675
-
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
-
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., Suzuki, T., Adachi, H., Miyazaki, T., Ishii, S., Kamata-Sakurai, M., Iida, T., Harada, A., Esaki, K., Funaki, M., Moriyama, C., Tanaka, E., Kikuchi, Y., Wakabayashi, T., Wada, M., Goto, M., Toyoda, T., Ueyama, A., Suzuki, S., Haraya, K., Tachibana, T., Kawabe, Y., Shima, M., Yoshioka, A. & Hattori, K. (2012) A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Medicine, 18, 1570-1574.
-
(2012)
Nature Medicine
, vol.18
, pp. 1570-1574
-
-
Kitazawa, T.1
Igawa, T.2
Sampei, Z.3
Muto, A.4
Kojima, T.5
Soeda, T.6
Yoshihashi, K.7
Okuyama-Nishida, Y.8
Saito, H.9
Tsunoda, H.10
Suzuki, T.11
Adachi, H.12
Miyazaki, T.13
Ishii, S.14
Kamata-Sakurai, M.15
Iida, T.16
Harada, A.17
Esaki, K.18
Funaki, M.19
Moriyama, C.20
Tanaka, E.21
Kikuchi, Y.22
Wakabayashi, T.23
Wada, M.24
Goto, M.25
Toyoda, T.26
Ueyama, A.27
Suzuki, S.28
Haraya, K.29
Tachibana, T.30
Kawabe, Y.31
Shima, M.32
Yoshioka, A.33
Hattori, K.34
more..
-
28
-
-
84923093912
-
Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
-
Kruse-Jarres, R., St-Louis, J., Greist, A., Shapiro, A., Smith, H., Chowdary, P., Drebes, A., Gomperts, E., Bourgeois, C., Mo, M., Novack, A., Farin, H. & Ewenstein, B. (2015) Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia, 21, 162-170.
-
(2015)
Haemophilia
, vol.21
, pp. 162-170
-
-
Kruse-Jarres, R.1
St-Louis, J.2
Greist, A.3
Shapiro, A.4
Smith, H.5
Chowdary, P.6
Drebes, A.7
Gomperts, E.8
Bourgeois, C.9
Mo, M.10
Novack, A.11
Farin, H.12
Ewenstein, B.13
-
29
-
-
79956291603
-
Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes
-
Lindhout, T., Iqbal, U., Willis, L.M., Reid, A.N., Li, J., Liu, X., Moreno, M. & Wakarchuk, W.W. (2011) Site-specific enzymatic polysialylation of therapeutic proteins using bacterial enzymes. Proceedings of the National Academy of Sciences of the United States of America, 108, 7397-7402.
-
(2011)
Proceedings of the National Academy of Sciences of the United States of America
, vol.108
, pp. 7397-7402
-
-
Lindhout, T.1
Iqbal, U.2
Willis, L.M.3
Reid, A.N.4
Li, J.5
Liu, X.6
Moreno, M.7
Wakarchuk, W.W.8
-
30
-
-
84922344657
-
A combinatorial library approach to generate rFVIII variants with multiple XTEN insertions and improved pharmacokinetic properties
-
PA 372.312-375.
-
Liu, T., Kulman, J., Chang, P.-Y.B., Patarroyo-White, S., Drager, D., Ding, S., Chhabra, E.S., Kumar, S., Pape, B., Moore, N., Bardan, S., Goodman, A., Acosta, M., Pierce, G.F., Schellenberger, V., Mei, B., Peteres, R.T. & Jiang, H. (2013) A combinatorial library approach to generate rFVIII variants with multiple XTEN insertions and improved pharmacokinetic properties. Journal of Thrombosis and Haemostasis, 11(Suppl. 2), 371. PA 372.312-375.
-
(2013)
Journal of Thrombosis and Haemostasis
, vol.11
, pp. 371
-
-
Liu, T.1
Kulman, J.2
Chang, P.-Y.3
Patarroyo-White, S.4
Drager, D.5
Ding, S.6
Chhabra, E.S.7
Kumar, S.8
Pape, B.9
Moore, N.10
Bardan, S.11
Goodman, A.12
Acosta, M.13
Pierce, G.F.14
Schellenberger, V.15
Mei, B.16
Peteres, R.T.17
Jiang, H.18
-
31
-
-
84930274386
-
Role of enhanced half-life factor VIII and IX in the treatment of haemophilia
-
Mahdi, A.J., Obaji, S.G. & Collins, P.W. (2015) Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. British Journal of Haematology, 169, 768-776.
-
(2015)
British Journal of Haematology
, vol.169
, pp. 768-776
-
-
Mahdi, A.J.1
Obaji, S.G.2
Collins, P.W.3
-
32
-
-
84860457217
-
Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia
-
Mahlangu, J.N., Coetzee, M.J., Laffan, M., Windyga, J., Yee, T.T., Schroeder, J., Haaning, J., Siegel, J.E. & Lemm, G. (2012) Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. Journal of Thrombosis & Haemostasis, 10, 773-780.
-
(2012)
Journal of Thrombosis & Haemostasis
, vol.10
, pp. 773-780
-
-
Mahlangu, J.N.1
Coetzee, M.J.2
Laffan, M.3
Windyga, J.4
Yee, T.T.5
Schroeder, J.6
Haaning, J.7
Siegel, J.E.8
Lemm, G.9
-
33
-
-
84899557335
-
Anti-drug antibody formation in haemophilia patients with inhibitors afterreceiving recombinant activated FVII analogue (vatreptacog alfa)
-
on behalf of the Adept Investigators. PO029.
-
Mahlangu, J., Karim, F.A., Gorska-Kosicka, M., Kaicker, S., Matsushita, T., Recht, M., Serban, M., Kentz, S., Weldingh, K.N. & Ehrenforth, S.; on behalf of the Adept Investigators. (2013) Anti-drug antibody formation in haemophilia patients with inhibitors afterreceiving recombinant activated FVII analogue (vatreptacog alfa). Haemophilia, 19, 10-82 PO029.
-
(2013)
Haemophilia
, vol.19
, pp. 10-82
-
-
Mahlangu, J.1
Karim, F.A.2
Gorska-Kosicka, M.3
Kaicker, S.4
Matsushita, T.5
Recht, M.6
Serban, M.7
Kentz, S.8
Weldingh, K.N.9
Ehrenforth, S.10
-
34
-
-
84857978849
-
Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia
-
Maroney, S.A., Cooley, B.C., Ferrel, J.P., Bonesho, C.E., Nielsen, L.V., Johansen, P.B., Hermit, M.B., Petersen, L.C. & Mast, A.E. (2012) Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proceedings of the National Academy of Sciences of the United States of America, 109, 3927-3931.
-
(2012)
Proceedings of the National Academy of Sciences of the United States of America
, vol.109
, pp. 3927-3931
-
-
Maroney, S.A.1
Cooley, B.C.2
Ferrel, J.P.3
Bonesho, C.E.4
Nielsen, L.V.5
Johansen, P.B.6
Hermit, M.B.7
Petersen, L.C.8
Mast, A.E.9
-
35
-
-
77955492929
-
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
-
Mei, B., Pan, C., Jiang, H., Tjandra, H., Strauss, J., Chen, Y., Liu, T., Zhang, X., Severs, J., Newgren, J., Chen, J., Gu, J.-M., Subramanyam, B., Fournel, M.A., Pierce, G.F. & Murphy, J.E. (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood, 116, 270-279.
-
(2010)
Blood
, vol.116
, pp. 270-279
-
-
Mei, B.1
Pan, C.2
Jiang, H.3
Tjandra, H.4
Strauss, J.5
Chen, Y.6
Liu, T.7
Zhang, X.8
Severs, J.9
Newgren, J.10
Chen, J.11
Gu, J.-M.12
Subramanyam, B.13
Fournel, M.A.14
Pierce, G.F.15
Murphy, J.E.16
-
36
-
-
70449461639
-
Genetic fusion to albumin improves the pharmacokinetic properties of factor IX
-
Metzner, H.J., Weimer, T., Kronthaler, U., Lang, W. & Schulte, S. (2009) Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thrombosis & Haemostasis, 102, 634-644.
-
(2009)
Thrombosis & Haemostasis
, vol.102
, pp. 634-644
-
-
Metzner, H.J.1
Weimer, T.2
Kronthaler, U.3
Lang, W.4
Schulte, S.5
-
37
-
-
84887009302
-
Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin
-
Metzner, H.J., Pipe, S.W., Weimer, T. & Schulte, S. (2013) Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thrombosis & Haemostasis, 110, 931-939.
-
(2013)
Thrombosis & Haemostasis
, vol.110
, pp. 931-939
-
-
Metzner, H.J.1
Pipe, S.W.2
Weimer, T.3
Schulte, S.4
-
38
-
-
64749104065
-
An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor
-
Muller, J., Isermann, B., Ducker, C., Salehi, M., Meyer, M., Friedrich, M., Madhusudhan, T., Oldenburg, J., Mayer, G. & Potzsch, B. (2009) An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor. Chemistry & Biology, 16, 442-451.
-
(2009)
Chemistry & Biology
, vol.16
, pp. 442-451
-
-
Muller, J.1
Isermann, B.2
Ducker, C.3
Salehi, M.4
Meyer, M.5
Friedrich, M.6
Madhusudhan, T.7
Oldenburg, J.8
Mayer, G.9
Potzsch, B.10
-
39
-
-
84911438456
-
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A
-
Muto, A., Yoshihashi, K., Takeda, M., Kitazawa, T., Soeda, T., Igawa, T., Sampei, Z., Kuramochi, T., Sakamoto, A., Haraya, K., Adachi, K., Kawabe, Y., Nogami, K., Shima, M. & Hattori, K. (2014) Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood, 124, 3165-3171.
-
(2014)
Blood
, vol.124
, pp. 3165-3171
-
-
Muto, A.1
Yoshihashi, K.2
Takeda, M.3
Kitazawa, T.4
Soeda, T.5
Igawa, T.6
Sampei, Z.7
Kuramochi, T.8
Sakamoto, A.9
Haraya, K.10
Adachi, K.11
Kawabe, Y.12
Nogami, K.13
Shima, M.14
Hattori, K.15
-
40
-
-
80052669248
-
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
-
Negrier, C., Knobe, K., Tiede, A., Giangrande, P. & Møss, J. (2011) Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood, 118, 2695-2701.
-
(2011)
Blood
, vol.118
, pp. 2695-2701
-
-
Negrier, C.1
Knobe, K.2
Tiede, A.3
Giangrande, P.4
Møss, J.5
-
41
-
-
80052167452
-
Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide
-
Østergaard, H., Bjelke, J.R., Hansen, L., Petersen, L.C., Pedersen, A.A., Elm, T., Møller, F., Hermit, M.B., Holm, P.K., Krogh, T.N., Petersen, J.M., Ezban, M., Sørensen, B.B., Andersen, M.D., Agersø, H., Ahmadian, H., Balling, K.W., Christiansen, M.L.S., Knobe, K., Nichols, T.C., Bjørn, S.E. & Tranholm, M. (2011) Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood, 118, 2333-2341.
-
(2011)
Blood
, vol.118
, pp. 2333-2341
-
-
Østergaard, H.1
Bjelke, J.R.2
Hansen, L.3
Petersen, L.C.4
Pedersen, A.A.5
Elm, T.6
Møller, F.7
Hermit, M.B.8
Holm, P.K.9
Krogh, T.N.10
Petersen, J.M.11
Ezban, M.12
Sørensen, B.B.13
Andersen, M.D.14
Agersø, H.15
Ahmadian, H.16
Balling, K.W.17
Christiansen, M.L.S.18
Knobe, K.19
Nichols, T.C.20
Bjørn, S.E.21
Tranholm, M.22
more..
-
42
-
-
84870336472
-
Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study
-
Powell, J., Martinowitz, U., Windyga, J., Di Minno, G., Hellmann, A., Pabinger, I., Maas Enriquez, M., Schwartz, L. & Ingerslev, J. (2012a) Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thrombosis and Haemostasis, 108, 913-922.
-
(2012)
Thrombosis and Haemostasis
, vol.108
, pp. 913-922
-
-
Powell, J.1
Martinowitz, U.2
Windyga, J.3
Di Minno, G.4
Hellmann, A.5
Pabinger, I.6
Maas Enriquez, M.7
Schwartz, L.8
Ingerslev, J.9
-
43
-
-
84859197329
-
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
-
Powell, J.S., Josephson, N.C., Quon, D., Ragni, M.V., Cheng, G., Li, E., Jiang, H., Li, L., Dumont, J.A., Goyal, J., Zhang, X., Sommer, J., McCue, J., Barbetti, M., Luk, A. & Pierce, G.F. (2012b) Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 119, 3031-3037.
-
(2012)
Blood
, vol.119
, pp. 3031-3037
-
-
Powell, J.S.1
Josephson, N.C.2
Quon, D.3
Ragni, M.V.4
Cheng, G.5
Li, E.6
Jiang, H.7
Li, L.8
Dumont, J.A.9
Goyal, J.10
Zhang, X.11
Sommer, J.12
McCue, J.13
Barbetti, M.14
Luk, A.15
Pierce, G.F.16
-
44
-
-
84889769562
-
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B
-
Powell, J.S., Pasi, K.J., Ragni, M.V., Ozelo, M.C., Valentino, L.A., Mahlangu, J.N., Josephson, N.C., Perry, D., Manco-Johnson, M.J., Apte, S., Baker, R.I., Chan, G.C., Novitzky, N., Wong, R.S., Krassova, S., Allen, G., Jiang, H., Innes, A., Li, S., Cristiano, L.M., Goyal, J., Sommer, J.M., Dumont, J.A., Nugent, K., Vigliani, G., Brennan, A., Luk, A. & Pierce, G.F. (2013) Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New England Journal of Medicine, 369, 2313-2323.
-
(2013)
New England Journal of Medicine
, vol.369
, pp. 2313-2323
-
-
Powell, J.S.1
Pasi, K.J.2
Ragni, M.V.3
Ozelo, M.C.4
Valentino, L.A.5
Mahlangu, J.N.6
Josephson, N.C.7
Perry, D.8
Manco-Johnson, M.J.9
Apte, S.10
Baker, R.I.11
Chan, G.C.12
Novitzky, N.13
Wong, R.S.14
Krassova, S.15
Allen, G.16
Jiang, H.17
Innes, A.18
Li, S.19
Cristiano, L.M.20
Goyal, J.21
Sommer, J.M.22
Dumont, J.A.23
Nugent, K.24
Vigliani, G.25
Brennan, A.26
Luk, A.27
Pierce, G.F.28
more..
-
45
-
-
33845549376
-
Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays
-
Radtke, K.P., Griffin, J.H., Riceberg, J. & Gale, A.J. (2007) Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. Journal of Thrombosis & Haemostasis, 5, 102-108.
-
(2007)
Journal of Thrombosis & Haemostasis
, vol.5
, pp. 102-108
-
-
Radtke, K.P.1
Griffin, J.H.2
Riceberg, J.3
Gale, A.J.4
-
47
-
-
0027394923
-
A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group
-
Rosendaal, F.R., Nieuwenhuis, H.K., van den Berg, H.M., Heijboer, H., Mauser-Bunschoten, E.P., van der Meer, J., Smit, C., Strengers, P.F. & Briet, E. (1993) A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood, 81, 2180-2186.
-
(1993)
Blood
, vol.81
, pp. 2180-2186
-
-
Rosendaal, F.R.1
Nieuwenhuis, H.K.2
van den Berg, H.M.3
Heijboer, H.4
Mauser-Bunschoten, E.P.5
van der Meer, J.6
Smit, C.7
Strengers, P.F.8
Briet, E.9
-
48
-
-
84867577250
-
Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII
-
Sandberg, H., Kannicht, C., Stenlund, P., Dadaian, M., Oswaldsson, U., Cordula, C. & Walter, O. (2012) Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thrombosis Research, 130, 808-817.
-
(2012)
Thrombosis Research
, vol.130
, pp. 808-817
-
-
Sandberg, H.1
Kannicht, C.2
Stenlund, P.3
Dadaian, M.4
Oswaldsson, U.5
Cordula, C.6
Walter, O.7
-
49
-
-
84866594053
-
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
-
Santagostino, E., Negrier, C., Klamroth, R., Tiede, A., Pabinger-Fasching, I., Voigt, C., Jacobs, I. & Morfini, M. (2012) Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood, 120, 2405-2411.
-
(2012)
Blood
, vol.120
, pp. 2405-2411
-
-
Santagostino, E.1
Negrier, C.2
Klamroth, R.3
Tiede, A.4
Pabinger-Fasching, I.5
Voigt, C.6
Jacobs, I.7
Morfini, M.8
-
50
-
-
84878831095
-
The immunogenicity of polyethylene glycol: facts and fiction
-
Schellekens, H., Hennink, W.E. & Brinks, V. (2013) The immunogenicity of polyethylene glycol: facts and fiction. Pharmaceutical Research, 30, 1729-1734.
-
(2013)
Pharmaceutical Research
, vol.30
, pp. 1729-1734
-
-
Schellekens, H.1
Hennink, W.E.2
Brinks, V.3
-
51
-
-
84875518350
-
Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII
-
Schulte, S. (2013) Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thrombosis Research, 131, S2-S6.
-
(2013)
Thrombosis Research
, vol.131
, pp. S2-S6
-
-
Schulte, S.1
-
52
-
-
84937764228
-
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
-
Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., Prabhala, H., Zhang, X., Attarwala, H., Hutabarat, R., Foster, D., Milstein, S., Charisse, K., Kuchimanchi, S., Maier, M.A., Nechev, L., Kandasamy, P., Kel'in, A.V., Nair, J.K., Rajeev, K.G., Manoharan, M., Meyers, R., Sorensen, B., Simon, A.R., Dargaud, Y., Negrier, C., Camire, R.M. & Akinc, A. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine, 21, 492-497.
-
(2015)
Nature Medicine
, vol.21
, pp. 492-497
-
-
Sehgal, A.1
Barros, S.2
Ivanciu, L.3
Cooley, B.4
Qin, J.5
Racie, T.6
Hettinger, J.7
Carioto, M.8
Jiang, Y.9
Brodsky, J.10
Prabhala, H.11
Zhang, X.12
Attarwala, H.13
Hutabarat, R.14
Foster, D.15
Milstein, S.16
Charisse, K.17
Kuchimanchi, S.18
Maier, M.A.19
Nechev, L.20
Kandasamy, P.21
Kel'in, A.V.22
Nair, J.K.23
Rajeev, K.G.24
Manoharan, M.25
Meyers, R.26
Sorensen, B.27
Simon, A.R.28
Dargaud, Y.29
Negrier, C.30
Camire, R.M.31
Akinc, A.32
more..
-
53
-
-
84862908041
-
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients
-
Shapiro, A.D., Ragni, M.V., Valentino, L.A., Key, N.S., Josephson, N.C., Powell, J.S., Cheng, G., Thompson, A.R., Goyal, J., Tubridy, K.L., Peters, R.T., Dumont, J.A., Euwart, D., Li, L., Hallén, B., Gozzi, P., Bitonti, A.J., Jiang, H., Luk, A. & Pierce, G.F. (2012) Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, 119, 666-672.
-
(2012)
Blood
, vol.119
, pp. 666-672
-
-
Shapiro, A.D.1
Ragni, M.V.2
Valentino, L.A.3
Key, N.S.4
Josephson, N.C.5
Powell, J.S.6
Cheng, G.7
Thompson, A.R.8
Goyal, J.9
Tubridy, K.L.10
Peters, R.T.11
Dumont, J.A.12
Euwart, D.13
Li, L.14
Hallén, B.15
Gozzi, P.16
Bitonti, A.J.17
Jiang, H.18
Luk, A.19
Pierce, G.F.20
more..
-
54
-
-
34447314172
-
Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients
-
Shetty, S., Vora, S., Kulkarni, B., Mota, L., Vijapurkar, M., Quadros, L. & Ghosh, K. (2007) Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. British Journal of Haematology, 138, 541-544.
-
(2007)
British Journal of Haematology
, vol.138
, pp. 541-544
-
-
Shetty, S.1
Vora, S.2
Kulkarni, B.3
Mota, L.4
Vijapurkar, M.5
Quadros, L.6
Ghosh, K.7
-
55
-
-
70350326031
-
X-linked thrombophilia with a mutant factor IX (factor IX Padua)
-
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N.P., Finn, J.D., Spiezia, L., Radu, C. & Arruda, V.R. (2009) X-linked thrombophilia with a mutant factor IX (factor IX Padua). New England Journal of Medicine, 361, 1671-1675.
-
(2009)
New England Journal of Medicine
, vol.361
, pp. 1671-1675
-
-
Simioni, P.1
Tormene, D.2
Tognin, G.3
Gavasso, S.4
Bulato, C.5
Iacobelli, N.P.6
Finn, J.D.7
Spiezia, L.8
Radu, C.9
Arruda, V.R.10
-
56
-
-
84955448713
-
A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in patients with hemophilia A or B
-
OR213.
-
Sorensen, B., Mant, T., Georgiev, P., Rangarajan, S., John Pasi, J., Creagh, D., Bevan, D., Austin, S., Hay, C., Brand, B., Simon, A., Melton, L., Lynam, C., Strahs, A., Sehgal, A., Hutabarat, R., Chaturvedi, P., Barros, P., Garg, P., Vaishnaw, A. & Akinc, A. (2014) A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in patients with hemophilia A or B. Journal of Thrombosis and Haemostasis, 13(S2), 176. OR213.
-
(2014)
Journal of Thrombosis and Haemostasis
, vol.13
, pp. 176
-
-
Sorensen, B.1
Mant, T.2
Georgiev, P.3
Rangarajan, S.4
John Pasi, J.5
Creagh, D.6
Bevan, D.7
Austin, S.8
Hay, C.9
Brand, B.10
Simon, A.11
Melton, L.12
Lynam, C.13
Strahs, A.14
Sehgal, A.15
Hutabarat, R.16
Chaturvedi, P.17
Barros, P.18
Garg, P.19
Vaishnaw, A.20
Akinc, A.21
more..
-
57
-
-
84877623981
-
A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
-
Stennicke, H.R., Kjalke, M., Karpf, D.M., Balling, K.W., Johansen, P.B., Elm, T., Ovlisen, K., Moller, F., Holmberg, H.L., Gudme, C.N., Persson, E., Hilden, I., Pelzer, H., Rahbek-Nielsen, H., Jespersgaard, C., Bogsnes, A., Pedersen, A.A., Kristensen, A.K., Peschke, B., Kappers, W., Rode, F., Thim, L., Tranholm, M., Ezban, M., Olsen, E.H.N. & Bjorn, S.E. (2013) A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood, 121, 2108-2116.
-
(2013)
Blood
, vol.121
, pp. 2108-2116
-
-
Stennicke, H.R.1
Kjalke, M.2
Karpf, D.M.3
Balling, K.W.4
Johansen, P.B.5
Elm, T.6
Ovlisen, K.7
Moller, F.8
Holmberg, H.L.9
Gudme, C.N.10
Persson, E.11
Hilden, I.12
Pelzer, H.13
Rahbek-Nielsen, H.14
Jespersgaard, C.15
Bogsnes, A.16
Pedersen, A.A.17
Kristensen, A.K.18
Peschke, B.19
Kappers, W.20
Rode, F.21
Thim, L.22
Tranholm, M.23
Ezban, M.24
Olsen, E.H.N.25
Bjorn, S.E.26
more..
-
58
-
-
84876182114
-
Enhancing the pharmacokinetic properties of recombinant factorVIII: first-in-human trial of glycoPEGylated recombinant factorVIII in patients with hemophiliaA
-
Tiede, A., Brand, B., Fischer, R., Kavakli, K., Lentz, S.R., Matsushita, T., Rea, C., Knobe, K. & Viuff, D. (2013) Enhancing the pharmacokinetic properties of recombinant factorVIII: first-in-human trial of glycoPEGylated recombinant factorVIII in patients with hemophiliaA. Journal of Thrombosis & Haemostasis, 11, 670-678.
-
(2013)
Journal of Thrombosis & Haemostasis
, vol.11
, pp. 670-678
-
-
Tiede, A.1
Brand, B.2
Fischer, R.3
Kavakli, K.4
Lentz, S.R.5
Matsushita, T.6
Rea, C.7
Knobe, K.8
Viuff, D.9
-
59
-
-
84921542285
-
The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule
-
Valentino, L.A., Cong, L., Enockson, C., Song, X., Scheiflinger, F., Muchitsch, E.M., Turecek, P.L. & Hakobyan, N. (2015) The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule. Haemophilia, 21, 58-63.
-
(2015)
Haemophilia
, vol.21
, pp. 58-63
-
-
Valentino, L.A.1
Cong, L.2
Enockson, C.3
Song, X.4
Scheiflinger, F.5
Muchitsch, E.M.6
Turecek, P.L.7
Hakobyan, N.8
-
60
-
-
53449102315
-
Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface
-
Wakabayashi, H., Varfaj, F., Deangelis, J. & Fay, P.J. (2008) Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood, 112, 2761-2769.
-
(2008)
Blood
, vol.112
, pp. 2761-2769
-
-
Wakabayashi, H.1
Varfaj, F.2
Deangelis, J.3
Fay, P.J.4
-
61
-
-
84920971123
-
Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors
-
Zakas, P.M., Vanijcharoenkarn, K., Markovitz, R.C., Meeks, S.L. & Doering, C.B. (2015) Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors. Journal of Thrombosis & Haemostasis, 13, 72-81.
-
(2015)
Journal of Thrombosis & Haemostasis
, vol.13
, pp. 72-81
-
-
Zakas, P.M.1
Vanijcharoenkarn, K.2
Markovitz, R.C.3
Meeks, S.L.4
Doering, C.B.5
-
62
-
-
84896919120
-
Discussion about several potential drawbacks of PEGylated therapeutic proteins
-
Zhang, F., Liu, M.R. & Wan, H.T. (2014) Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biological and Pharmaceutical Bulletin, 37, 335-339.
-
(2014)
Biological and Pharmaceutical Bulletin
, vol.37
, pp. 335-339
-
-
Zhang, F.1
Liu, M.R.2
Wan, H.T.3
-
63
-
-
84902547350
-
Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII
-
Zollner, S., Raquet, E., Claar, P., Muller-Cohrs, J., Metzner, H.J., Weimer, T., Pragst, I., Dickneite, G. & Schulte, S. (2014) Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thrombosis Research, 134, 125-131.
-
(2014)
Thrombosis Research
, vol.134
, pp. 125-131
-
-
Zollner, S.1
Raquet, E.2
Claar, P.3
Muller-Cohrs, J.4
Metzner, H.J.5
Weimer, T.6
Pragst, I.7
Dickneite, G.8
Schulte, S.9
|